52 results
6-K
EX-99.1
PPBT
Purple Biotech Ltd
13 Feb 24
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
7:10am
commitment to advancing patient care through clinical research. With approximately 350 publications to his name, Dr. Adkins serves on committees including
6-K
EX-4.4
PPBT
Purple Biotech Ltd
19 Oct 23
Report of Foreign Private Issuer
10:36am
that, in consideration for the Holder’s participation in the Offering and purchase of Securities in the Offering (the “Purchase Commitment”), the Company … Commitment. In the event that either (i) the Offering is not consummated or (ii) the Holder does not satisfy the Purchase Commitment, the Warrant Amendment
424B5
PPBT
Purple Biotech Ltd
19 Oct 23
Prospectus supplement for primary offering
10:27am
and prospective investors. The engagement agreement does not give rise to any commitment by the Placement Agent to purchase any of our securities …
The securities being offered by this prospectus may be sold:
through agents;
to or through one or more underwriters on a firm commitment or agency basis
6-K
EX-99.2
PPBT
Purple Biotech Ltd
22 Aug 23
Purple Biotech Reports Second Quarter 2023 Financial Results
8:22am
and in the Group’s operations. The Group acts to develop an effective control environment in which all employees understand their roles and commitment
F-3/A
fdtx7fbfncenjsv
17 May 23
Shelf registration (foreign) (amended)
5:20pm
F-3
risyfw
7 Dec 22
Shelf registration (foreign)
9:17pm
6-K
EX-99.2
ll2ifirb
4 Aug 22
Purple Biotech Reports Second Quarter 2022 Financial Results
7:31am
6-K
EX-99.1
3mk2gtlhze5o4sbxtg
14 Jul 22
Purple Biotech Announces Executive Leadership Changes
7:31am
6-K
EX-99.1
fxlhrtd8axu2k71hd6o
4 Feb 22
Purple Biotech Issues Letter to Shareholders
8:31am
6-K
EX-99.2
5b9 zefdc07
5 Aug 21
Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results
8:33am
424B5
7i19k0lbzbfz
9 Jun 21
Prospectus supplement for primary offering
4:54pm
20-F/A
y86nt
16 Mar 21
Annual report (foreign) (amended)
3:22pm
6-K
EX-99.2
8vktqw3h6whwsrd2l
10 Dec 20
Report of Foreign Private Issuer
8:19am
6-K
EX-99.1
qq193y
17 Aug 20
Report of Foreign Private Issuer
6:07am
6-K
EX-99.2
nkj8344nz za
11 Aug 20
Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results
8:22am
6-K
EX-1.2
pu0wbvgot1udv65
25 Jun 20
Report of Foreign Private Issuer
11:16am
424B5
q1rtd132v8fknqy3w38u
25 Jun 20
Prospectus supplement for primary offering
11:13am